Paradigm BioDevices marked the completion of 40,000 procedures utilizing the QUICKDRAW MIS Bone Grafting System. QuickDraw is a percutaneous or MIS bone grafting system developed to address risk factors associated with iliac crest bone grafting.
QuickDraw employs a tiny MIS or percutaneous incision to excise precise quantities of morselized autograft bone. Numerous independent and Level 1 metadata studies have confirmed that MIS autograft can be taken both safely and effectively with fewer patient complications and superior fusion rates than bone substitutes.
“We are grateful for the continued confidence and support we’ve received from our valued customers and distributors,” says Founder & President Mike O’Neill. “In an era when industry competitors are spending tens of millions marketing bone graft substitutes attacking the efficacy of autograft, we are thrilled to see the unwavering appreciation for, and continuous acceptance of, our MIS autografting products.”
Paradigm BioDevices marked the completion of 40,000 procedures utilizing the QUICKDRAW MIS Bone Grafting System. QuickDraw is a percutaneous or MIS bone grafting system developed to address risk factors associated with iliac crest bone grafting.
QuickDraw employs a tiny MIS or percutaneous incision to excise precise quantities of morselized...
Paradigm BioDevices marked the completion of 40,000 procedures utilizing the QUICKDRAW MIS Bone Grafting System. QuickDraw is a percutaneous or MIS bone grafting system developed to address risk factors associated with iliac crest bone grafting.
QuickDraw employs a tiny MIS or percutaneous incision to excise precise quantities of morselized autograft bone. Numerous independent and Level 1 metadata studies have confirmed that MIS autograft can be taken both safely and effectively with fewer patient complications and superior fusion rates than bone substitutes.
“We are grateful for the continued confidence and support we’ve received from our valued customers and distributors,” says Founder & President Mike O’Neill. “In an era when industry competitors are spending tens of millions marketing bone graft substitutes attacking the efficacy of autograft, we are thrilled to see the unwavering appreciation for, and continuous acceptance of, our MIS autografting products.”
Copy to clipboard 
